OMCL Stock Recent News

Omnicell, Inc. (NASDAQ:OMCL ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Kathleen Nemeth - Senior Vice President, Investor Relations Randall Lipps - Founder, Chairman, President and CEO Scott Seidelmann - Executive Vice President and CCO Peter Kuipers - Executive Vice President and CFO Conference Call Participants Stan Berenshteyn - Wells Fargo Securities Matt Hewitt - Craig-Hallum Capital Group Scott Schoenhaus - KeyBanc Jessica Tassan - Piper Sandler Bill Sutherland - The Benchmark Company David Larsen - BTIG Stephanie Davis - SVB Securities Allen Lutz - the Bank of America Operator Ladies and gentlemen, thank you for standing by. Welcome to the Omnicell Fourth Quarter 2022 Financial Results Call.

Omnicell (OMCL) delivered earnings and revenue surprises of 266.67% and 3.97%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

SANTA CLARA, Calif.

Omnicell has a record of volume growth but volatile profitability and is experiencing poor order visibility. Operating in a competitive market with the healthcare industry under pressure from rising costs, we believe demand for automated pharmacy solutions will fall in priority.

SANTA CLARA, Calif.--( BUSINESS WIRE )--Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, announced that they will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 8:15 a.m. Pacific Time.

Macroeconomic factors adversely affect bookings and revenues in Omnicell's (OMCL) point-of-care business. The company reduces its overall bookings and revenue outlook for the year.

SANTA CLARA, Calif.--( BUSINESS WIRE )--Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, announced its participation in the upcoming investor conference:

Rise in operating expenses result in an operating loss in Q3 for Omnicell (OMCL), placing significant pressure on the bottom line.

The healthcare medication management company released lowered guidance.

Omnicell, Inc. (NASDAQ:OMCL ) Q3 2022 Earnings Conference Call November 2, 2022 8:30 AM ET Company Participants Kathleen Nemeth - Senior Vice President, Investor Relations Randall Lipps - Chairman, President, Chief Executive Officer, and Founder Scott Seidelmann - Executive Vice President and Chief Commercial Officer Peter Kuipers - Executive Vice President and Chief Financial Officer Conference Call Participants Stan Berenshteyn - Wells Fargo Securities Jessica Tassan - Piper Sandler Allen Lutz - Bank of America Scott Schoenhaus - KeyBanc Matt Hewitt - Craig-Hallum Capital Group Dev Weerasuriya - Berenberg Capital Management Joy Zeng - SVB Securities Anne Samuel - JP Morgan David Larsen - BTIG Operator Ladies and gentlemen, thank you for standing-by. My name is [Brent] [ph] and I will be your conference operator today.